youtube_live
Q3 2026 earnings • in 3 days
See detailschevron_right
GSK:NYSE
GSK plc
$50.75
arrow_downward
-0.90%(-0.46) 1D
$50.75
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 23, 4:00:03 PM GMT-4 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GSK...
Open
$50.83
High
$50.92
Low
$50.29
Mkt. cap
102.78B
Avg. vol.
4.94M
Volume
3.18M
Dividend
3.58%
Quarterly dividend
$0.45
Ex-dividend date
Aug 13, 2026
P/E ratio
16.05
52-wk high
$61.70
52-wk low
$42.84
EPS
$3.16
Beta
0.25
Shares outstanding
2.16B
No. of employees
67K
Open
$50.83
High
$50.92
Low
$50.29
Mkt. cap
102.78B
Avg. vol.
4.94M
Volume
3.18M
Dividend
3.58%
Quarterly dividend
$0.45
Ex-dividend date
Aug 13, 2026
P/E ratio
16.05
52-wk high
$61.70
52-wk low
$42.84
EPS
$3.16
Beta
0.25
Shares outstanding
2.16B
No. of employees
67K
News stories
From web sources and news partners
Yahoo Finance
·
1 day ago
Can Specialty Meds Offset GSK’s $2.2B Legal Charges and Sizzling R&D Setbacks on Oct. 28?
Big News Network.com
·
2 days ago
UAE's investments in digital health initiatives create opportunities to strengthen preventive care, advance medical innovation: GSK
Yahoo Finance
·
2 days ago
How First In Class Hepatitis B Approval At GSK (LSE:GSK) Has Changed Its Investment Story
Yahoo Finance
·
2 days ago
GSK (LSE:GSK) Stock May Trade At A Discount Despite Hibsago Approval
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees66.8K
FoundedDec 27, 2000
Headquarters-
SectorPharmaceutical industry
Websitegsk.com
Analyst ratings
Based on 2 analysts giving stock ratings to GSK in the past 3 months
Buy
Buy
1
Hold
1
Sell
0
12-month forecast
Based on 2 Wall Street analysts offering 12 month price targets for GSK in the last 3 months.
Highest
Current $50.75
$70.00 (+37.93%)
Average
$65.00 (+28.08%)
Lowest
$60.00 (+18.23%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Unknown Analyst Berenberg Bank | Buy | Upgraded | $60.00 | +18.2% | 09/15/2026 |
Steve Scala TD Cowen | Hold | Maintained | $70.00 | +37.9% | 08/03/2026 |
Jasper Hellweg Argus Research | Buy | Maintained | - | - | 06/08/2026 |
Michael Leuchten Jefferies | Buy | Maintained | $67.10 | +32.2% | 05/29/2026 |
Unknown Analyst Citi | Hold | Initiated | - | - | 01/29/2026 |
Next call in 3 days
Wed, Oct 28, 8:00 AM
Fiscal period
Q3 2026
- Normalized EPS / Est. (GBP)
- GAAP EPS / Est. (GBP)
- / £1.33
Revenue / Est. (GBP)
- / 8.83B
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in GBP
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in GBP | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 8.55B | 8.62B | 7.63B | 8.41B |
Cost of goods sold | 2.24B | 2.62B | 1.87B | 2.07B |
Cost of revenue | 2.24B | 2.62B | 1.87B | 2.07B |
Research and development expenses | 1.58B | 2.14B | 1.52B | 1.75B |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 2.16B | 2.67B | 2.08B | 2.19B |
Operating expense | 3.23B | 4.37B | 2.99B | 3.74B |
Total operating expenses | 5.46B | 6.99B | 4.86B | 5.81B |
Operating income | 3.08B | 1.63B | 2.77B | 2.60B |
Other non operating income | - | -21.00M | - | - |
EBT including unusual items | 2.46B | 950.00M | 2.14B | 354.00M |
EBT excluding unusual items | 2.94B | 1.48B | 2.62B | 2.48B |
Income tax expense | 312.00M | 223.00M | 305.00M | -199.00M |
Effective tax rate | 12.70% | 23.47% | 14.23% | -56.21% |
Other operating expenses | -511.00M | -434.00M | -615.00M | -204.00M |
Net income | 2.01B | 636.00M | 1.74B | 435.00M |
Net profit margin | 23.55% | 7.38% | 22.77% | 5.17% |
Earnings per share | 0.55 | - | - | - |
Interest and investment income | 26.00M | 17.00M | 22.00M | 58.00M |
Interest expense | -167.00M | -145.00M | -167.00M | -182.00M |
Net interest expenses | -141.00M | -128.00M | -145.00M | -124.00M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | 3.82B | 2.69B | 3.23B | 2.82B |
Gain or loss from assets sale | - | -40.00M | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events